Last updated on January 2020

Phase 1 Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma


Brief description of study

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.

Clinical Study Identifier: NCT02834780

Find a site near you

Start Over

UC Irvine Medical Center

Orange, CA United States
  Connect »

UCLA Medical Center

Santa Monica, CA United States
  Connect »

Northwestern Unversity

Chicago, IL United States
  Connect »

McGuire VA Medical Center

Richmond, VA United States
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Hoag Memorial Hospital Presbyterian

Newport Beach, CA United States
  Connect »